US-Listed In Vitro & In Vivo Diagnostic Substances — Net Income Percentiles, FY 2020

Population: 21 US-listed companies (SIC 2835), fiscal year 2020; fiscal year ends 2020-06-30 to 2021-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$-134.2M
25th percentile	$-37.3M
Median	$-13.5M
75th percentile	$3.6M
90th percentile	$581.8M
Mean	$65.0M
Minimum	$-223.6M
Maximum	$810.3M

Methodology & sources
Net Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2020 = fiscal years ending 2020-06-01 to 2021-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Net Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/net-income/2020